Surgical Science Sweden AB (publ) (SUS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to this quarter one presentation for surgical science. My name is Tom Englund. I'm the CEO of surgical science. And with me today I have Anna Ahlberg, our company CFO. We will use our time together today to first present the report and then we will take questions from the audience. We can look back at an eventful and positive first quarter for Surgical Science and a good start of 2025. This was an eventful quarter for us with strong growth and good underlying profitability. Sales increased to 251 million SEK up from 188 million last year with a growth of 30% in local currencies. During the quarter, we also reached an all-time high for our important license revenue, which grew more than 30% as the robotic surgery market continues to expand. I will now present the most important highlights and results of the business during the quarter. Starting with Intelligent Ultrasound, the company was welcomed into the surgical science family during the quarter. Intelligent ultrasound is a prominent player within ultrasound simulation, and the acquisition makes surgical science the world leader within this field, which is a market with big growth potential. The integration process has progressed well during the quarter, and it's gratifying to see that the synergies identified before the acquisitions are now actually becoming apparent in practice. We're working according to a plan to realize these synergies, which are primarily found in distribution channels, strengthened sales presence in direct markets, cross-selling of products, and in long-term product development. During the quarter, we also officially opened up our direct sales office in the UK. The acquisition and integration resulted in some one-off costs related to transaction and restructuring that negatively impa...